Prevalence and Risk Factors for Minor Hallucinations in Patients with Parkinson’s Disease

Table 3

Clinical characteristics of the PD-MH and PD-NH patients.

	PD-total	PD-MH	PD-NH	Value		Adjusted value^b	Adjusted ^b
NMS-Quest,				3157	<0.0001^a	23.154	<0.0001^a
PDSS,				3691.5	<0.001^a	7.486	0.007^a
MoCA,				5080.5	0.752^a	0.675	0.412^a
Visuospatial/executive,				4915	0.478^a	0.776	0.379^a
Naming,				4836.5	0.166^a	1.028	0.312^a
Attention,				5095.5	0.724^a	0.347	0.556^a
Language,				4948	0.389^a	1.241	0.267^a
Abstraction,				4930.5	0.447^a	0.773	0.380^a
Delayed memory,				5061.5	0.714^a	0.007	0.931^a
Orientation,				5119.5	0.751^a	0.084	0.773^a
HAMA,				4302.5	0.034^a	3.624	0.058^a
HAMD,				4961	0.554^a	0.180	0.672^a
PDQ39,				4074.5	0.008^a	5.485	0.020^a
RBDSQ,				3741.5	0.001^a	9.114	0.003^a

^aMann-Whitney test. ^bThe value and are calculated adjusted for disease duration and LEDD. ^cSignificant results are highlighted in italic (). SD: standard deviation; PD: Parkinson’s disease; MH: minor hallucination; NH: no hallucinations; NMS-Quest: Non-Motor Symptoms Questionnaire; PDSS: the PD Sleep Scale; MOCA: Montreal Cognitive Assessment; HAMA: Hamilton Anxiety Rating Scale; HAMD: Hamilton Depression Rating Scale; PDQ39: Parkinson’s Disease Questionnaire-39; RBDSQ: the REM Sleep Behavior Disorder Sleep Questionnaire.